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corporeal circuit, ischemia-reperfusion injury, and tis-
sue trauma. These events are associated with activation
of a number of complex and interrelated pathways that
include the coagulation, fibrinolytic, kallikrein, and
complement systems; endotoxin release and cytokine
production; white blood cell and platelet activation;
endothelial activation and expression of leukocyte
adhesion molecules; and production of nitric oxide,
oxygen radicals, and proteolytic enzymes.1-4 Thus ther-
apies to modulate inflammatory signaling are desirable.
Unfortunately, the effect of interventions directed
against the systemic inflammatory response (eg, specific
receptor or enzyme blockade) in models of inflamma-
tion or CPB has been modest, at least in part because of
the diverse and interconnected nature of the pathways
involved. More general therapies, such as steroids, have
widely known undesirable side effects.
C ardiopulmonary bypass (CPB) and cardiac opera-tion stimulate inflammatory responses because of
several factors, including blood contact with the extra-
Objective: The systemic inflammatory response is an important cause of
organ dysfunction. The present study tested the hypothesis that 2 clini-
cally used agents, amrinone and vesnarinone, would decrease inflamma-
tion and cardiac dysfunction in a relevant model of systemic inflamma-
tory response activation. Methods: Rabbits received intravenous
endotoxin, alone or in conjunction with amrinone or vesnarinone.
Systemic effects were assessed by death, fever, behavior, and acidosis.
Measures of inflammatory signaling were (1) plasma tumor necrosis fac-
tor-a and interleukin-1b production, (2) lung tissue myeloperoxidase
activity, and (3) myocardial inducible nitric oxide synthase activity.
Indices of systolic and diastolic myocardial function were measured in
Langendorff-perfused hearts. Results: Vesnarinone, in particular,
reduced mortality rates (19% vs 61% for lipopolysaccharide alone, P =
.01) and acidosis in lipopolysaccharide-treated rabbits. Both agents
markedly reduced systemic tumor necrosis factor and interleukin-1 con-
centrations, lipopolysaccharide-mediated effects on myocardial systolic
and diastolic function and on myocardial inducible nitric oxide synthase
activity. Vesnarinone, but not amrinone, (1) decreased fever and lethar-
gy, consistent with decreased central nervous system effects of endotox-
in, and (2) decreased lung leukocyte infiltration. Conclusions: Vesnarinone
and amrinone, which are used clinically for their inotropic and vasodi-
lating properties, may be useful to limit inflammatory activation and
consequent organ dysfunction. Structure-activity and/or pharmacokinet-
ic between the compounds may be important, particularly in preventing
inflamatory signaling within certain tissues. (J Thorac Cardiovasc Surg
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Phosphodiesterase inhibitors, such as amrinone and
milrinone, have been used for their inotropic and
vasodilating properties to treat heart failure. Recently,
diverse immunomodulating properties have been attrib-
uted to various members of this family of compounds,
including decreased myocardial inflammation and T-
cell activity in experimental myocarditis5-7 and de-
creased proinflammatory cytokine production in both
humans8 and experimental models.9-11 These results
and reports that increased cytokine production occurs
in human heart failure12 have led to speculation that the
anti-inflammatory actions of these compounds may be
responsible for the clinical improvements in cardiac
function that have been observed at concentrations that
are not inotropic.8 Thus the purpose of the present
study was to test the hypothesis that 2 clinically used
agents, amrinone and vesnarinone, would significantly
reduce inflammatory signaling in a model of severe
systemic inflammatory response produced by intra-
venous endotoxin administration.
Methods
Reagents. The vesnarinone was a gift from Otsuka
Pharmaceutical Co (Tokushima, Japan). All other chemicals
were purchased from Sigma Chemical Company (St Louis,
Mo), unless otherwise noted and were of the highest grade
available. Salmonella typhimurium endotoxin (lipopolysac-
charide; lot 121H4025) was also purchased from Sigma
Chemical Company. Cell culture reagents were from Life
Technologies (Gaithersburg, Md).
Experimental protocol. Animal procedures received insti-
tutional approval and were conducted in conformity with the
“Guiding Principles in the Care and Use of Animals” of the
American Physiology Society and the “Guide for the Care
and Use of Laboratory Animals” published by the National
Institutes of Health (NIH publication No. 85-23, revised,
1985). New Zealand White rabbits (2.5-3.0 kg) were given
either intravenous endotoxin (0.2 mg/kg) dissolved in 1
mL/kg sterile saline solution (lipopolysaccharide-treated
group) or sterile saline solution alone (1 mL/kg; control
group). Two other groups received either intravenous vesnar-
inone (3 mg/kg as a single bolus) or amrinone (1 mg/kg bolus
plus 10 µg/ kg/min continuous infusion) concomitant with the
lipopolysaccharide infusion. Mean arterial blood pressure
was recorded continuously from an indwelling catheter in an
ear artery. Hearts from animals thus treated were either used
for contractility studies or prepared for measurements of in-
ducible nitric oxide synthase (iNOS) activity. All animals
received intravenous lactated Ringer’s solution at a rate of 10
mL/kg/h for the duration of study.
Clinical effects of endotoxemia. Temperature (tympanic
membrane) and clinical appearance were assessed hourly.
Animals were given a behavioral lethargy score by an observer,
blinded to treatment status, as follows: 0 = normal activity; 1
= quiet, spontaneous activity; 2 = no spontaneous movement,
but responsive (withdrawal) to touch; 3 = responds only to
noxious stimuli; 4 = unresponsive to noxious stimuli.
Plasma tumor necrosis factor-a and interleukin-1b con-
centrations. Approximately 1 mL of arterial blood was col-
lected from at 0, 1, 2, and 6 hours. The blood was rapidly cen-
trifuged (3000g for 5 min at 4°C) and frozen at –80°C. Plasma
tumor necrosis factor-a (TNF-a ) concentrations were mea-
sured by an enzyme-linked immunosorbent assay (ELISA)
with polygonal goat anti-rabbit TNF capture antibody (4-8
m g/mL), biotin-conjugated goat anti-rabbit TNF detection anti-
body (2 m g/mL), and streptavidin horseradish peroxidase con-
jugate (all from Pharmingen, San Diego, Calif) as per the man-
ufacturer’s instructions. TNF from activated rabbit peritoneal
macrophages (Pharmingen) was used as standard. The lower
limit of detection was 10 pg/mL; the assay was linear between
25 to 2000 pg/mL; the assay coefficient of variation was 9%.
Plasma interleukin-1b (IL-1b ) was measured with a commer-
cially available solid-phase ELISA according to the manufac-
turer’s instructions (Biotrak, Amersham, Buckinghamshire,
England). The IL-1b assay was linear between 15 and 1000
pg/mL, with a lower limit of detection of 10 pg/mL and assay
a coefficient of variation of 6%.
Pulmonary inflammation. Samples of lung tissue were
rapidly excised, rinsed free of blood in ice-cold phosphate-
buffered saline solution, and immediately frozen in liquid
nitrogen. Lung myeloperoxidase activity was measured as
previously described.13 Lung tissue (approximately 5 g) was
homogenized and then briefly sonicated in 50 mmol/L potas-
sium phosphate buffer (pH 6.0) containing 0.5% hexade-
cyltrimethylammonium bromide. After centrifugation at
5000g at 4°C for 10 minutes, the supernatant (0.1 mL) was
mixed with 2.9 mL of potassium phosphate buffer containing
0.167 mg/mL o-dianisidine dihydrochloride and 0.0005%
hydrogen peroxide. The reaction occurred at room tempera-
ture with the absorbance change measured at 460 nm over 3
minutes. One unit of myeloperoxidase activity was defined as
that degrading 1 m mol peroxide per minute.
Isolated heart preparation. Six hours after lipopolysac-
charide, lipopolysaccharide + vesnarinone, or lipopolysac-
charide + amrinone, animals received ketamine, xylazine,
and heparin (1000 units) intravenously; their hearts were then
rapidly excised and placed in ice-cold Krebs-Henseleit buffer.
The composition of the buffer was NaCl, 140 mmol/L; CaCl2,
1.25 mmol/L; KCl, 4.7 mmol/L; glucose, 11.0 mmol/L;
MgSO4, 1.2 mmol/L; NaHC03, 25 mmol/L; NaH2PO4, 0.5
mmol/L; bovine regular insulin, 10 U/L, was also included.
Hearts were then rapidly perfused retrograde through the
aorta in the Langendorff mode at 80 mm Hg constant pres-
sure with 37°C buffer that had been equilibrated with a 95%
oxygen and 5% carbon dioxide gas mixture and passed
through a 0.2- m m filter. The final buffer pH was 7.35 to 7.45;
the PO2 was 500 to 600 mm Hg, and the PCO2 was 30 to 40
mm Hg. The pulmonary outflow tract was incised and cannu-
lated. A latex fluid-filled balloon connected to a micro-
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manometry catheter (Millar Instruments, Houston, Texas)
was used for isovolumic left ventricular (LV) function mea-
surements. The balloon was inserted into the left ventricle
and sewn to the mitral anulus to prevent herniation; balloon
volume was varied with a calibrated, fluid-filled syringe.
Hearts were enclosed in a water-jacketed chamber; myocar-
dial temperature was monitored continuously with a thermis-
tor placed in the right ventricle and maintained between 36°C
to 37°C.
Peak developed LV pressure and LV end-diastolic pressure
were measured at 5 different LV balloon volumes. For the
purposes of statistical comparison of diastolic function, pres-
sure-volume data from each heart was entered into the equa-
tion P = bekv+c, as described by Glantz and Parmely,14 which
we have used previously.15 Alterations in compliance were
assessed as (1) chamber stiffness, calculated from the slope
of this relationship as dP/dV at end-diastolic pressure (EDP)
= 10 cm H2O, and (2) chamber volume, estimated from the
balloon volume necessary at EDP = 0 ( D V0). Coronary flow
was measured by timed collection of the coronary effluent.
Oxygen content was calculated from the measured oxygen
tension (ABL-3 Acid-Base Laboratory, Radiometer, A/S,
Copenhagen, Denmark) of aortic perfusate and coronary
venous effluent samples; myocardial oxygen consumption
was calculated as the measured arteriovenous oxygen differ-
ence multiplied by coronary flow.
iNOS activity. Calcium-independent nitric oxide enzyme
activity (corresponding to iNOS, a key enzyme induced by
proinflammatory cytokine signaling) was determined in the
crude cytosolic fraction of LV myocardium by the conversion
of radiolabeled arginine to citrulline, as we have previously
described.16 Hearts were rapidly isolated and flushed with
ice-cold homogenization buffer, which was comprised of 25
mmol/L Tris HCl, 2 mmol/L EGTA, 2 mmol/L EDTA, 2
mmol/L phenylmethylsulfonyl fluoride, 25 m g/mL leupeptin,
and 0.3 mol/L sucrose, pH 7.5; the hearts were then snap
frozen in liquid nitrogen.
Approximately 2 g of left ventricular myocardium was
homogenized at 4°C with a polytron homogenizer and cen-
trifuged at 1000g for 10 minutes. The supernatant was then
centrifuged at 100,000g for 1 hour at 4°C. The supernatant
was saved as crude cytosol. The reaction buffer consisted of
20 mmol/L N-tris[hydroxymethyl]methyl-2-aminoethanesul-
fonic acid, 2 mmol/L dithiothreitol, 10% glycerol, and the
aforementioned protease inhibitors. This was supplemented
with 5 mmol/L tetrahydrobiopterin, 5 m mol/L flavin mononu-
cleotide, 2.5 mmol/L NADPH, 25 mmol/L L-arginine, 1.0
mmol/L EGTA, 50 mmol/L valine (to inhibit arginase activi-
ty), and [2,3,4,5–3 H]-L-arginine hydrochloride (final specific
activity 0.1 mCi/mL). The reaction was initiated by the addi-
tion of crude cytosol (in a 1:1 ratio of cytosol/reaction mix-
ture), proceeded for 1 hour at room temperature, and was ter-
minated by the addition of 20 mmol/L citric acid, pH 4.0, in
a ratio of 4:1 (citric acid/reaction mixture). Arginine was sep-
arated from citrulline by slowly passing the samples over a
cation exchange column (Polypore Sulfoprophy1 10 m m, 2.1
· 30 mm; Applied Biosystems, Foster City, Calif) for 8 min-
utes; citrulline was eluted with 0.02 mmol/L citric acid, pH.
2.0. Enzyme activity was expressed as picomoles of arginine
converted to citrulline per hour per milligram of protein.
Protein content was measured by the bicinchonic acid
method (Pierce, Rockford, Ill) with bovine serum albumin
used as standard.
Statistical analyses. All data are presented as mean ± SD.
Differences in mortality rates between groups were com-
pared with 2 · 2 contingency tables and Fisher’s exact test
(2-tailed). Multiple group comparisons were made with the
Kruskal-Wallis test or analysis of variance followed by the
Bonferroni procedure. For the purposes of statistical analy-
sis, cytokine concentrations of 10 pg/mL or less (the lower
limit of detection of the ELISA) were given a value of
0 pg/mL.
Results
Endotoxemia model. The mortality rate after
lipopolysaccharide in the various groups is shown in
Table I. An increase in body temperature was seen in
lipopolysaccharide-treated animals but not in those that
received lipopolysaccharide with vesnarinone; interest-
Table I. Death, fever, and behavior after endotoxin
Time (h) LPS LPS+AMR P value vs LPS LPS+VES P value vs LPS
Alive (No.) 0 18 12 16
2 15 12 15
6 7 9 .07* 13 .01*
Temperature (°C) 0 37.6 ± 0.3 37.8 ± 0.4 37.5 ± 0.3
2 38.9 ± 0.6 39.9 ± 1.0 .20 38.1 ± 0.5 .04†
6 39.1 ± 0.5 39.0 ± 0.6 NS 38.0 ± 0.4 .01†
Lethargy score (0-4) 0 0 0 0
2 2.5 ± 0.5 2.5 ± 0.5 NS 1.0 ± 0.5 .03†
6 3.0 ± 0.5 2.0 ± 0.5 .15 0.5 ± 0.5 .01†
LPS, Lipopolysaccharide; AMR, amrinone; VES, vesnarinone; NS, not significant. Data are mean ± SD.
*Fisher’s exact test, 2-tailed.
†Kruskal-Wallis.
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ingly, fever was also sustained in animals that received
lipopolysaccharide + amrinone (Table I). Endotoxemic
animals and those that received lipopolysaccharide +
amrinone were also more lethargic than the animals
that received vesnarinone (Table I). No endotoxemic
animal that received vesnarinone achieved a lethargy
score of 3 or greater at any point during the 6-hour
study period, whereas 50% of those that received
lipopolysaccharide alone did so.
Mean arterial blood pressure in surviving lipopolysac-
charide-treated animals was 71 ± 3 mm Hg, 66 ± 3 mm
Hg, 63 ± 3 mm Hg, 59 ± 3 mm Hg, and 62 ± 4 mm Hg
at 0, 1, 2, 4, and 6 hours after lipopolysaccharide admin-
istration, respectively. These values were not different at
any of the time points in the lipopolysaccharide + amri-
none or lipopolysaccharide + vesnarinone animals. Thus
mean blood pressure did not appear to be affected by the
drug treatments, and hypotension was not present before
the hearts were isolated for Langendorff perfusion.
Serum bicarbonate was consistently lower in lipo-
polysaccharide-treated animals beginning 1 to 2 hours
after lipopolysaccharide administration. The nadir value
was 10 ± 1 mmol/L (vs 21 ± 2 mmol/L in control ani-
mals; P = .02). This abnormality was corrected some-
what by amrinone (14 ± 3 mmol/L) and more so by ves-
narinone (18 ± 2; P = .05 vs lipopolysaccharide alone).
Markers of inflammatory activation. The effects of
the different treatments on plasma TNF-a and IL-1b in
endotoxemic animals are shown in Fig l, A and B,
respectively.
Lipopolysaccharide significantly increased lung
myeloperoxidase activity 6 hours after exposure; this
change was prevented by vesnarinone but not by amri-
none (Fig 2).
Differences in the calcium-independent conversion
of radiolabeled L-arginine (the nitric oxide precursor)
to L-citrulline are shown in Fig 3. Lipopolysaccharide
caused a significant increase in myocardial iNOS activ-
ity that was markedly attenuated in lipopolysaccharide-
treated animals who had also received vesnarinone and,
to a somewhat lesser extent, amrinone.
Cardiac function. The effects on rate · pressure
product (RPP), myocardial oxygen consumption, and
derived indices of diastolic function (dP/dV, D V0) in
the different treatment groups are shown in Table II.
As can be seen, both amrinone and vesnarinone pre-
vented lipopolysaccharide-induced reductions in RPP.
Interestingly, vesnarinone-treated lipopolysaccharide-
treated hearts were substantially more efficient, using
significantly less oxygen per unit work (RPP/myocar-
dial oxygen consumption ratio). Diastolic function was
significantly impaired by lipopolysaccharide and
improved in animals that received either amrinone or
vesnarinone.
Discussion
There has been increasing recognition of the impor-
tance of various effectors and mechanisms of inflam-
mation in the pathogenesis of sepsis, ischemia-reperfu-
sion, and rejection. The multiple mechanisms of
A B
Fig 1. Cytokine production in response to endotoxin. Data are mean ± SD; n = 8 each. A, Plasma TNF-a in ani-
mals treated with lipopolysaccharide (LPS) alone, lipopolysaccharide + vesnarinone (VES), or lipopolysaccharide
+ amrinone (AMR). B, Plasma IL-1b concentrations. Both vesnarinone and amrinone significantly suppressed
lipopolysaccharide-stimulated TNF and IL-1 production compared with lipopolysaccharide alone (analysis of
variance/Bonferroni).
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 2
Takeuchi et al   379
inflammatory activation associated with CPB (eg, trau-
ma, ischemia-reperfusion, contact activation, coagula-
tion/fibrinolysis) make it in many ways the most sig-
nificant and diffuse of clinical models. This study did
not use CPB. Nonetheless, the findings are also rele-
vant to CPB. Most directly, endotoxemia has been fre-
quently (although not universally) found to occur dur-
ing CPB.1 Ischemia-reperfusion can rapidly promote
intramyocardial TNF production.17 Endotoxemia acti-
vates cytokine, complement, white cell, and adhesion
molecule pathways, all of which are also activated by
CPB. Indeed, many of the deleterious effects of CPB
have been attributed to these interrelated inflammatory
cascades. Thus many of the mechanisms of organ dys-
function in endotoxemia and CPB (eg, ischemia-reper-
fusion, white cell infiltration, nitric oxide, and oxyrad-
ical production) are qualitatively similar.
The most important finding of this study was that ves-
narinone and amrinone, to somewhat different degrees,
prevented or reduced many different features of the acute
endotoxemic response. These included lipopolysac-
charide-induced death, fever, acidosis, cardiac dysfunc-
tion, and elevated plasma cytokine concentrations.
Because vesnarinone has unique pharmacologic effects
unrelated to type III phosphodiesterase inhibition,
including Na+ channel opening, decreased inward and
outward K+ currents, and prolonged action potential
duration in the heart,18-20 we studied the effects of amri-
Fig 2. Lung myeloperoxidase activity was reduced by ves-
narinone (VES) treatment (P = .03) compared with either
lipopolysaccharide (LPS) alone or lipopolysaccharide + amri-
none (AMR). Data are mean ± SD; n = 4 each.
Fig 3. Calcium-independent nitric oxide synthase activity in
myocardial extracts from animals treated with lipopolysac-
charide (LPS) alone, lipopolysaccharide + vesnarinone
(VES), or lipopolysaccharide + amrinone (AMR). Data are
mean ± SD; n = 6 each. Both vesnarinone and amrinone
reduced iNOS activity resulting from lipopolysaccharide
treatment (analysis of variance/Bonferroni, P = .04).
Table II. Myocardial function in Langendorff-perfused, endotoxin hearts
P value P value P value 
Sham LPS vs control* LPS+AMR vs LPS* LPS+VES vs LPS*
Rate pressure product 16.2 ± 2.2 10.1 ± 3.0 .03 14.8 ± 3.2 .1 15.9 ± 2.0 .04
(mm Hg/s · 103)
Oxygen consumption 48 ± 7 65 ± 8 .06 69 ± 12 .4 42 ± 10 .04
(mL/min/g)
Chamber stiffness 11.4 ± 2.3 17.1 ± 3.1 .04 12.8 ± 3.1 .05 12.1 ± 2.5 .05
(dP/dV @ EDP = 10)
Chamber volume at EDP = 0 0.7 ± 0.1 0.3 ± 0.2 .03 0.6 ± 0.1 .05 0.8 ± 0.1 .01
(D V0)
LPS, Lipopolysaccharide; AMR, amrinone; VES, vesnarinone; EDP, end-diastolic pressure. Data are mean ± SD. 
*Analysis of variance/Bonferroni.
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none in the same model. Previous studies have demon-
strated varying potency of type III and IV phosphodi-
esterase inhibitors to decrease production of cytokines
and other markers of inflammation in response to proin-
flammatory stimuli.21-23 The exact mechanism of action
is uncertain but is likely to include increased intracellu-
lar cyclic adenosine monophosphate (cAMP) concentra-
tions9; for example, increased cAMP blocks lipopolysac-
charide-mediated TNF gene transcription.9,22-24 This
effect may be specific for TNF, however, because
increased cAMP does not prevent production of IL-6
under similar circumstances.22 Furthermore, vesnarinone
but not amrinone prevented natural killer cell activity
and TNF-a production in a murine model of acute viral
myocarditis,6 which also suggests that some of vesnari-
none’s anti-inflammatory effects may not be common to
all phosphodiesterase inhibitors.
Other reports have documented inhibition of second
messenger signaling in response to proinflammatory
and membrane-damaging stimuli, particularly by
means of phosphatidic acid release from membrane
lipids.25,26 The ability to prevent “stress-induced” cel-
lular activation in response to the activation of specific
membrane receptors or membrane damage may under-
lie the wide range of effects on cytokine production,
neutrophil activation, and organ function. Because the
primary role of phosphatidic acid signaling appears to
be to respond to various forms of cellular stress, its
inhibition may preferentially target cells exposed to
activating events while minimally affecting normal
cells; this may offer a potential advantage compared
with other agents such as corticosteroids.25
There were some important differences between
amrinone and vesnarinone in this model. Amrinone
demonstrated a minimal ability to decrease pulmonary
leukocyte infiltration as measured by lung myeloperox-
idase activity. Whether this was due to less potent
effects on leukocyte signaling mechanisms (eg, IL-8,
adhesion molecule production) or other mechanisms
requires further delineation. Intriguing was the sugges-
tion that vesnarinone had greater effect on fever and
“sickness behavior” despite equivalent effects on sys-
temic cytokine concentrations. Fever and behavioral
changes caused by lipopolysaccharide can be attributed
to specific areas within the central nervous system.27
Endotoxemia and cytokines are believed to affect the
brain indirectly by stimulating meningeal macrophages
and perivascular microglia to produce prostaglandins
and other signaling compounds27; whether vesnarinone
has greater inhibitory effect on these pathways remains
to be determined. However, it should also be empha-
sized that plasma (or brain) vesnarinone and amrinone
concentrations were not measured and dose-response
effects not studied. Important differences exist in dif-
ferent cell types with regard to phosphodiesterase iso-
form content (eg, phosphodiesterase III or IV) and the
sensitivity of these isoforms to phosphodiesterase
inhibitors. For example, vesnarinone may display some
degree of selectivity for the cardiac phosphodiesterase
III isoform, inhibiting neutrophil and monocyte phos-
phodiesterase IV at significantly higher concentra-
tions.28 Thus pharmacokinetic or pharmacodynamic
explanations for any observed differences between the
2 drugs cannot be excluded.
The significance of the present study is that it sug-
gests that agents such as vesnarinone or amrinone may
be useful to modulate several aspects of the inflamma-
tory response. Although vesnarinone has been found to
improve myocardial performance in patients with heart
failure, prolonged use of high-dose oral vesnarinone
increased mortality rates.20 The responsible mecha-
nisms were uncertain, but it is unlikely that a similar
result would occur given the much shorter duration
(12-24 hours) of therapy that would be needed in the
setting of CPB. It is likely, however, that this interven-
tion would need to be combined with agents affecting
other pathways for optimal effects.
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Discussion
Dr Edward D. Verrier (Seattle, Wash). Most of the time
we would use phosphodiesterase inhibitors after the event. I
have 2 questions. 
Do you think that ischemia-reperfusion would precipitate
similar responses or is this more consistent with an inflam-
matory stimuli like TNF or IL-1 or lipopolysaccharide? 
Have you done any studies where the event occurs and then
you give vesnarinone and then look at some of the markers of
inflammation? Can you give it later or does this have to be
something that is on board before?
Dr Takeuchi. I think I will try to answer the second ques-
tion first. We tried vesnarinone treatment after a couple of
hours after injection of lipopolysaccharide, but the effect we
got was not so dramatic, so that is why we administered the
vesnarinone simultaneously. 
Regarding your first question, I think that the next model to
study probably is the CPB model. We just focused on this
simple, severe model to test the effect of this drug, to see if it
is effective or not; so the results are actually positive. I think
the next step will be to try to do the CPB model. 
Dr del Nido. I would like to add a comment to what Dr
Takeuchi said. In fact, what we are trying to address here is
the inflammatory response to CPB. The interesting finding is
that if you treat, in essence almost pretreat, or treat simulta-
neously, you get a profound reduction in the inflammatory
response. We were accustomed to using these drugs as
inotropes after ischemia. They do have some effect in
improving function after ischemia, obviously, but there may
be a role for them as a pretreatment modality.
Dr Verrier. Is there a disadvantage to treating somebody with
it before bypass? Have you done the model in bypass at all? 
Dr del Nido. We have not done the model in bypass. The
disadvantage is the vasodilatory properties of amrinone.
Vesnarinone is certainly not as potent for that. So probably
vesnarinone would be the better drug to test.
Dr Christopher A. Caldarone (Boston, Mass). In relation
to the reperfusion question, working in Dr Levitsky’s laborato-
ry in Boston, we actually investigated milrinone in a large ani-
mal model of ischemia-reperfusion injury (Ann Thorac Surg
1994;57:540-5). Surprisingly, in the nonischemic controls, we
were not able to detect evidence of improved contractility or
diastolic function in the absence of an ischemic injury. 
After an ischemia-reperfusion injury with global normo-
thermic ischemia, administration of milrinone in the reperfu-
sion period actually had only a moderate improvement in
contractility but a very dramatic improvement in early dias-
tolic relaxation. Our impression was that the efficacy of phos-
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phodiesterase inhibition was somehow limited to ischemia-
reperfusion injury. Your data would suggest that we should
reinterpret our results and perhaps what we were really see-
ing was an amelioration of an inflammatory response after
the reperfusion injury. 
My one question is that the end-diastolic pressure/volume
relationship tends to be a better index of the extent of late
diastolic relaxation. In contrast, early diastolic relaxation is
commonly estimated with tau, the constant of isovolumic
relaxation, which more accurately reflects calcium handling
events occurring in early diastole. Did you find a difference
in the early diastolic function?
Dr Takeuchi. Actually I did measure diastolic pressure/
volume in these groups, but there was no difference between
those groups. In terms of the diastolic constant tau, it is sig-
nificantly different.
